Changes for page Array BioPharma

Last modified by Asif Farooqui on 2019/09/18 17:38
From version < 1.2 >
edited by Asif Farooqui
on 2019/09/18 17:33
To version < 2.1 >
edited by Asif Farooqui
on 2019/09/18 17:34
< >
Change comment: There is no comment for this version

Summary

Details

Page properties
Content
... ... @@ -4,7 +4,7 @@
4 4  
5 5  = =
6 6  
7 -Array is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule cancer therapies. Eight registration studies are currently advancing related to seven Array-owned or partnered drugs: binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Cascadian Therapeutics).
7 +Array (ARRY) is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule cancer therapies. Eight registration studies are currently advancing related to seven Array-owned or partnered drugs: binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Cascadian Therapeutics).
8 8  
9 9  The company have received a total of $1.0 billion in research funding and in up-front and milestone payments from partners from inception through June 30, 2017 , including $292.0 million in initial payments from strategic agreements that The company entered into over the last ten years. The company received an up-front cash payment of $85.0 million upon the March 2015 effective date of the asset transfer agreement with Novartis for binimetinib, $30.0 million in January 2016 from Pierre Fabre and $31.2 million in June 2017 from Ono. Its existing partnered programs entitle Array to receive a total of over $2.7 billion in additional milestone payments if The company or its partners achieve the drug discovery, development and commercialization objectives detailed in those agreements. The company also have the potential to earn royalties on any resulting product sales or share in the proceeds from licensing or commercialization from 17 partnered clinical and discovery programs. The potential milestones The company are entitled to receive are further described in Note 5 – Collaboration and Other Agreements to its financial statements included elsewhere in this Annual Report on Form 10-K.
10 10  
This site is funded and maintained by Fintel.io